HIGHLIGHTS
- who: Gerhild Wildner from the University of Kent, United Kingdom have published the paper: A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis u2014 A phase I clinical trial, in the Journal: (JOURNAL)
- what: The authors show the results of a prospective, first in man phase 1 clinical trial in patients with posterior uveitis, the type of autoimmune disease, which has the greatest risk for retinal destruction and permanent vision loss. The primary study objective was to assess the safety and tolerability of ascending doses . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.